VG901 / ViGeneron - LARVOL DELTA

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: ViGeneron GmbH | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa

ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial (GlobeNewswire) - "ViGeneron GmbH...announced two important milestones for its novel gene therapy candidate VG901, to treat patients with retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene. The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to VG901, and the independent Data Safety Monitoring Board (DSMB) has unanimously approved dose escalation in the ongoing Phase 1b clinical trial."

DSMB • FDA event • Retinitis Pigmentosa

ViGeneron Announces First Patient Dosed in Phase 1b Clinical Trial of VG901 for the Intravitreal Treatment of Retinitis Pigmentosa (GlobeNewswire) - "ViGeneron GmbH...today announced that the first patient has been dosed in its Phase Ib clinical trial evaluating intravitreal injection of VG901 to treat retinitis pigmentosa (RP) caused by mutations in the CNGA1 gene....VG901 has also been granted FDA Orphan Drug Designation status."

Orphan drug • Trial status • Retinitis Pigmentosa

Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene (clinicaltrials.gov) - P1 | N=6 | Recruiting | Sponsor: ViGeneron GmbH

New P1 trial • Genetic Disorders • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Retinal Disorders • Retinitis Pigmentosa